6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Laser: new trials by email Literature Review of Laser trials Research Report on Laser
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients Ranibizumab (RFB002), Laser, Sham injection - Diabetic Macular Edema, Visual Impairment | Phase 3 | Completed | Novartis Pharmaceuticals | 384 | 2014-11-05 | 2019-02-01 |
| Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Ranibizumab, Laser - Branch Retinal Vein Occlusion | Phase 3 | Completed | Novartis Pharmaceuticals | 455 | 2012-05-01 | 2016-11-10 |
| Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion ranibizumab, Peripheral Laser - Retinal Vein Occlusion | Phase 3 | Completed | Peter A Campochiaro, MD | 66 | 2010-08-01 | 2014-01-13 |
| Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) ranibizumab, Laser - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 241 | 2010-07-01 | 2014-10-23 |
| A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study Ranibizumab, Laser, Sham laser - Diabetic Macular Edema | Phase 3 | Completed | Novartis | 345 | 2008-05-01 | 2013-04-01 |
| Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation criopexy, laser - Rhegmatogenous Retinal Detachment | Phase 3 | Completed | University of Campinas, Brazil | 86 | 2006-07-01 | 2010-05-26 |
Macular Edema (3) · Vision Disorders (3) · Diabetes Mellitus (2) · Retinal Vein Occlusion (2) · Edema (1) · Retinal Diseases (1)
Novartis Pharmaceuticals (3) · Novartis (1) · Peter A Campochiaro, MD (1) · University of Campinas, Brazil (1)
Canada (3) · Australia (2) · France (2) · Greece (2) · Hungary (2) · Italy (2) · Netherlands (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · China (1) · Czechia (1) · Denmark (1) · Germany (1)
PMID 21149772, PMID 21459215, PMID 23974915, PMID 24491642, PMID 25148789, PMID 26327116, PMID 26584450, PMID 27039022, PMID 28807635, PMID 34934034